Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Sanfang Tu, Langqi Wang, Shaojie Wu, Yanjie He, Chaoyang Song, Zhao Liang, Xuan Zhou, Lei Wang, Chunyan Yue, Lijuan Zhou, Jilong Yang, Yuhua Li

Blood (2025) 146 (Supplement 1): 8045.

https://doi.org/10.1182/blood-2025-8045

Published: 2025

Journal Articles

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

Zhijuan Lin, Long Liu, Manman Deng, Xingxing Yu, Yan Hong, Hua Wang, Keshu Zhou, Shaojie Wu, Ting-Bo Liu, Na Qin, Rui Su, Zhifeng Li, Bing Xu

Blood (2025) 146 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2025-1818

Published: 2025

Journal Articles

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Sanfang Tu, Kaixin Ou, Lei Wang, Xuan Zhou, Chaoyang Song, Shaojie Wu, Rui Huang, Yanjie He, Yuxian Huang, Chunyan Yue, Minhong Huang, Yuhua Li

Blood (2025) 146 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2025-3353

Published: 2025

Journal Articles

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Zhifeng Li, Hua Wang, Zhijuan Lin, Li Yu, Shaojie Wu, Na Qin, Jie Zha, Long Liu, Manman Deng, Bing Xu

Blood (2025) 146 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2025-3580

Published: 2025

Journal Articles

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Sanfang Tu, Minhong Huang, Chaoyang Song, Yuxian Huang, Rui Huang, Yanjie He, Shaojie Wu, Xuan Zhou, Jilong Yang, Chunyan Yue, Lei Wang, Yuhua Li

Blood (2025) 146 (Supplement 1): 7754.

https://doi.org/10.1182/blood-2025-7754

Published: 2025

Journal Articles

Deep learning-based tumor microenvironment profiling predicts CAR-t efficacy and guides combinatorial immunotherapy in B-cell lymphoma

Shaojie Wu, Jiatong Wang, Jiaxiu Li

Blood (2025) 146 (Supplement 1): 5331.

https://doi.org/10.1182/blood-2025-5331

Published: 2025

Journal Articles

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Shaojie Wu, Yanni Deng, Mingyao Lai, Sanfang Tu, Linbo Cai, Yuhua Li

Blood (2024) 144 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2024-200645

Published: 2024

Journal Articles

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Shaojie Wu, Junru Du, Jie Ma, Li Huang, Zhiqiang Peng, Yiwen Ling, Xiaofang Deng, Weijian Zhu, Hongliang Li, Hua Wang, Yuhua Li

Blood (2024) 144 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2024-200667

Published: 2024

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

Shaojie Wu, Sanfang Tu, Zhenjun Zhou, Xinlin Sun, Anqin Wu, Lei Wang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2023-181471

Published: 2023

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Deep learning-based tumor microenvironment profiling predicts CAR-t efficacy and guides combinatorial immunotherapy in B-cell lymphoma

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only